Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Cutter

Showing results (81-90 of 333) with videos related to

Pageof 34
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2023
The impact of relapse definition and measures of durability on MS clinical trial outcomesSammita Satyanarayan, Gary Cutter, Stephen Krieger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2005
Validation of the NARCOMS registry: fatigue assessmentRuth Ann Marrie, Gary Cutter, Tuula Tyry, et al.
Multiple Sclerosis and Related Disorders|April 21, 2015
Natalizumab reduces relapse clinical severity and improves relapse recovery in MSFred D Lublin, Gary Cutter, Gavin Giovannoni, et al.
Neurology. Clinical Practice|November 17, 2016
Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MSAmber Salter, Tuula Tyry, Guoqiao Wang, et al.
The Journal of Infectious Diseases|October 22, 2024
Neutralizing Antibody Responses to Chlamydia trachomatis in Women and Associations With Chlamydia OutcomesHong Yu, William M Geisler, Chuanbin Dai, et al.
Multiple Sclerosis and Related Disorders|April 21, 2019
Evaluation of a web-based fall prevention program among people with multiple sclerosisMeena Kannan, Andrea Hildebrand, Cinda L Hugos, et al.
Muscle & Nerve|June 8, 2022
One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient RegistryIkjae Lee, Justin M Leach, Inmaculada Aban, et al.
Neurology|July 10, 2013
Mortality in patients with multiple sclerosisAntonio Scalfari, Volker Knappertz, Gary Cutter, et al.
Neurology|October 27, 2020
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple SclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
European Journal of Neurology|January 15, 2021
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?Marcus W Koch, Jop Mostert, Pavle Repovic, et al.
Pageof 34

Showing results (81-90 of 333) with videos related to

Sort By:
Pageof 34
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2023
The impact of relapse definition and measures of durability on MS clinical trial outcomesSammita Satyanarayan, Gary Cutter, Stephen Krieger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2005
Validation of the NARCOMS registry: fatigue assessmentRuth Ann Marrie, Gary Cutter, Tuula Tyry, et al.
Multiple Sclerosis and Related Disorders|April 21, 2015
Natalizumab reduces relapse clinical severity and improves relapse recovery in MSFred D Lublin, Gary Cutter, Gavin Giovannoni, et al.
Neurology. Clinical Practice|November 17, 2016
Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MSAmber Salter, Tuula Tyry, Guoqiao Wang, et al.
The Journal of Infectious Diseases|October 22, 2024
Neutralizing Antibody Responses to Chlamydia trachomatis in Women and Associations With Chlamydia OutcomesHong Yu, William M Geisler, Chuanbin Dai, et al.
Multiple Sclerosis and Related Disorders|April 21, 2019
Evaluation of a web-based fall prevention program among people with multiple sclerosisMeena Kannan, Andrea Hildebrand, Cinda L Hugos, et al.
Muscle & Nerve|June 8, 2022
One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient RegistryIkjae Lee, Justin M Leach, Inmaculada Aban, et al.
Neurology|July 10, 2013
Mortality in patients with multiple sclerosisAntonio Scalfari, Volker Knappertz, Gary Cutter, et al.
Neurology|October 27, 2020
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple SclerosisMarcus W Koch, Jop Mostert, Pavle Repovic, et al.
European Journal of Neurology|January 15, 2021
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?Marcus W Koch, Jop Mostert, Pavle Repovic, et al.
Pageof 34